Market Closed -
Nasdaq
04:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
25.84
USD
|
-9.33%
|
|
-26.38%
|
0.00%
|
Fiscal Period: December |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,722
|
-
|
-
|
Enterprise Value (EV)
1 |
1,516
|
1,588
|
1,474
|
P/E ratio
|
-15.2
x
|
-12.8
x
|
-18.5
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,037
x
|
157
x
|
18
x
|
EV / Revenue
|
913
x
|
144
x
|
15.4
x
|
EV / EBITDA
|
-15.9
x
|
-14.8
x
|
-29.1
x
|
EV / FCF
|
-14.2
x
|
-11
x
|
-10.3
x
|
FCF Yield
|
-7.07%
|
-9.06%
|
-9.68%
|
Price to Book
|
7.95
x
|
13.7
x
|
14.2
x
|
Nbr of stocks (in thousands)
|
66,640
|
-
|
-
|
Reference price
2 |
25.84
|
25.84
|
25.84
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1.661
|
11
|
95.4
|
EBITDA
1 |
-
|
-55.43
|
-95.42
|
-107
|
-50.56
|
EBIT
1 |
-
|
-55.45
|
-100.5
|
-123.4
|
-95.65
|
Operating Margin
|
-
|
-
|
-6,047.05%
|
-1,122.27%
|
-100.26%
|
Earnings before Tax (EBT)
1 |
-
|
-48.61
|
-96.19
|
-121.6
|
-98.52
|
Net income
1 |
-35.44
|
-48.61
|
-88.31
|
-111.9
|
-98.52
|
Net margin
|
-
|
-
|
-5,315.93%
|
-1,016.91%
|
-103.27%
|
EPS
2 |
-11.73
|
-15.65
|
-1.705
|
-2.022
|
-1.400
|
Free Cash Flow
1 |
-
|
-45.68
|
-107.2
|
-143.9
|
-142.7
|
FCF margin
|
-
|
-
|
-6,450.26%
|
-1,308.55%
|
-149.6%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/27/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
0.529
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.93
|
-22.47
|
-22.79
|
-25.75
|
-27.44
|
-29.65
|
-
|
Operating Margin
|
-
|
-4,247.45%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-16.93
|
-24.9
|
-27.1
|
-29.5
|
-
|
-
|
Net income
1 |
-
|
-16.93
|
-24.9
|
-27.1
|
-29.5
|
-
|
-
|
Net margin
|
-
|
-3,200.76%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.3600
|
-0.4075
|
-0.4475
|
-0.4750
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
188
|
206
|
134
|
248
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-45.7
|
-107
|
-144
|
-143
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-220%
|
-52.1%
|
-13.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-28.40
|
3.250
|
1.880
|
1.820
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
2.09
|
2.4
|
2.85
|
Capex / Sales
|
-
|
-
|
125.81%
|
21.82%
|
2.99%
|
Announcement Date
|
10/27/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
25.84
USD Average target price
68.2
USD Spread / Average Target +163.93% Consensus |
1st Jan change
|
Capi.
|
---|
| 0.00% | 1.72B | | +26.37% | 48.16B | | -1.01% | 41.73B | | +43.57% | 41.03B | | -5.31% | 28.77B | | +9.34% | 25.59B | | -21.69% | 18.96B | | +6.23% | 12.92B | | +26.99% | 12.03B | | -3.38% | 11.77B |
Other Biotechnology & Medical Research
|